Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
Oric Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to discovering and developing innovative therapies for the treatment of cancer. Headquartered in South San Francisco, California, Oric Pharmaceuticals was founded in 2014 and has since focused on addressing the challenging problem of cancer resistance to existing treatments.
The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor. This receptor has been identified as a key player in the resistance mechanisms against various classes of cancer therapeutics, particularly across solid tumors. By targeting this receptor, ORIC-101 aims to enhance the effectiveness of existing cancer treatments.
Another significant asset in Oric's pipeline is ORIC-533, an orally bioavailable small molecule inhibitor of CD73. CD73 plays a role in resistance to both chemotherapy and immunotherapy, and ORIC-533 is being developed to counteract this resistance, offering a potential new avenue for treating patients who do not respond to current therapies.
In addition to ORIC-101 and ORIC-533, the company is also developing ORIC-944 and ORIC-114, each targeting different mechanisms of cancer resistance. ORIC-944 has shown promise in initial Phase 1b data, and the company has outlined several anticipated milestones for these programs in the near future.
Oric Pharmaceuticals demonstrates a robust commitment to advancing the field of precision oncology. The company leverages its expertise in hormone-dependent cancers, precision oncology, and key tumor dependencies to build a diverse pipeline of therapies. These efforts are supported by strategic partnerships and collaborations aimed at accelerating the development and commercialization of their treatment candidates.
Financially, Oric Pharmaceuticals has provided guidance and updates to keep stakeholders informed about their progress and strategic direction. For the latest news and developments, investors and interested parties are encouraged to stay tuned to the company's announcements.
Contact: Dominic Piscitelli, Chief Financial Officer
ORIC Pharmaceuticals announced promising preclinical data for ORIC-533, a potent CD73 inhibitor for multiple myeloma, showcasing its potential to overcome immunosuppression. The drug demonstrated significant activity in assays from patients, indicating potential as a single-agent therapy. A Phase 1 trial is set to start in Q4 2021. Additional updates include progress on ORIC-114 and ORIC-944, with trials expected in early 2022. The data highlights the need for effective treatments in patients exhibiting therapeutic resistance.
ORIC Pharmaceuticals, focused on therapies for cancer resistance, is hosting a conference call on December 13, 2021, at 5:30 p.m. ET to discuss their CD73 inhibitor for multiple myeloma. Senior author Dr. Kenneth Anderson will highlight new ex vivo data presented at the ASH Annual Meeting, showcasing how CD73 inhibition combats immune suppression and boosts antitumor activity. The ASH presentation occurs on December 12, 2021. This event aims to provide insights into the clinical potential of ORIC-533, a molecule targeting key resistance pathways in cancer.
ORIC Pharmaceuticals, a clinical stage oncology company, will participate in two upcoming investor conferences. The Jefferies London Health Conference is scheduled for November 18, 2021, at 8:00 a.m. GMT, followed by the Evercore ISI 4th Annual HealthconX Conference on December 2, 2021, at 3:55 p.m. ET. Both events will feature virtual fireside chats available on their website. ORIC is focused on developing cancer treatments targeting therapeutic resistance, with lead candidate ORIC-101 currently in Phase 1b trials.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced the appointment of Dr. Angie You to its board of directors, effective immediately. Dr. You, the current CEO of Amunix Pharmaceuticals, brings extensive experience in venture capital and business development, which ORIC believes will strengthen its leadership as it advances its oncology pipeline. Concurrently, Carl L. Gordon, Ph.D., resigned from the board. ORIC is focused on developing innovative cancer therapies, with lead candidate ORIC-101 currently in Phase 1b trials targeting therapeutic resistance in solid tumors.
ORIC Pharmaceuticals reported financial results for Q3 2021, highlighting a cash position of $296.5 million expected to fund operations into 2024. Initial clinical data from the Phase 1b trial of ORIC-101 in combination with enzalutamide showed a safe profile and preliminary antitumor activity in metastatic prostate cancer. The company also submitted a CTA for ORIC-114 and plans to initiate a Phase 1 trial for ORIC-533 in multiple myeloma. R&D expenses rose to $12.9 million, reflecting increased efforts on product candidates.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced significant advancements regarding ORIC-533, a potent CD73 inhibitor, expected to begin Phase 1 trials in patients with multiple myeloma in 4Q 2021. A preclinical study presented at the ASH Annual Meeting revealed that CD73 inhibition effectively reversed immune suppression and enhanced T-cell activity against tumor cells in relapsed or refractory multiple myeloma patients. The findings highlight the potential of ORIC-533 to improve cancer treatments by overcoming therapeutic resistance.
ORIC Pharmaceuticals has announced initial data from a Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide for metastatic prostate cancer. The combination was well tolerated, with adverse events aligning with enzalutamide alone. ORIC-101 showed effective GR suppression and maintained target plasma concentrations without drug-drug interaction. Notably, in patients with moderate to high GR expression, there’s evidence of extended treatment duration. ORIC-114 demonstrated compelling preclinical activity in HER2-positive breast cancer.
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical-stage oncology company, will present three posters at the AACR-NCI-EORTC Virtual Conference from October 7-10, 2021. These presentations will cover key findings from their Phase 1b studies involving ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide for patients with metastatic prostate cancer, and the preclinical results of ORIC-114, an irreversible kinase inhibitor for HER2-positive breast cancer. A conference call to discuss the data will be held on October 7 at 9:00 a.m. ET.
ORIC Pharmaceuticals (Nasdaq: ORIC) has announced that the FDA has cleared its IND application for ORIC-533, a CD73 inhibitor, to proceed into a first-in-human clinical trial. This trial will evaluate ORIC-533 as a standalone treatment for a tumor type not previously investigated with other CD73 inhibitors. Preclinical studies show ORIC-533 has higher potency and efficacy in blocking adenosine-driven immunosuppression compared to current alternatives. The first patient is expected to be enrolled in Q4 2021. ORIC plans additional IND filings for other product candidates in the same quarter.
ORIC Pharmaceuticals will participate in several investor conferences in September 2021. Key events include a panel on targeted oncology at Citi’s 16th Annual BioPharma Virtual Conference on September 10, a company overview at the H.C. Wainwright Conference on September 13, and a fireside chat at the Oppenheimer Summit on September 22. Webcasts will be accessible on the company’s website for 90 days post-event. ORIC is developing innovative oncology treatments, including ORIC-101, targeting resistance mechanisms in cancer therapy.
FAQ
What is the current stock price of Oric Pharmaceuticals (ORIC)?
What is the market cap of Oric Pharmaceuticals (ORIC)?
What is Oric Pharmaceuticals, Inc.?
What is ORIC-101?
What is ORIC-533?
Where is Oric Pharmaceuticals headquartered?
When was Oric Pharmaceuticals founded?
What other products are in Oric Pharmaceuticals' pipeline?
What are the core areas of expertise for Oric Pharmaceuticals?
How can I contact Oric Pharmaceuticals for more information?
What is the company’s financial condition?
What recent achievements has Oric Pharmaceuticals made?
